Mechanistic description
This strategy combines LDLR upregulation-mediated cholesterol transport machinery priming with engineered endosomal escape mechanisms to achieve superior CNS antibody delivery. The approach begins with targeted pharmacological or gene therapy-based upregulation of LDLR expression in brain microvascular endothelial cells, which primes the cellular cholesterol transport infrastructure and enhances co-expressed LRP1 receptor density and trafficking efficiency. Therapeutic antibodies are conjugated to high-affinity APOE-mimetic peptides that specifically target the upregulated LRP1 receptors, facilitating rapid receptor-mediated endocytosis across the blood-brain barrier. The critical innovation involves engineering these antibody-APOE conjugates with pH-responsive fusogenic peptides that remain inactive at physiological pH (7.4) but undergo conformational activation in the acidic endosomal environment (pH 5.5-6.0). Upon endocytosis, the acidification-triggered fusogenic domains disrupt endosomal membranes, liberating therapeutic antibodies directly into the cytoplasm and preventing lysosomal degradation. This dual-priming mechanism leverages LDLR’s well-characterized transcytotic machinery to enhance LRP1-mediated transport capacity while simultaneously solving the post-transcytotic degradation problem through engineered endosomal escape. The strategy predicts 50-200 fold improvements in CNS antibody bioavailability compared to passive FcRn transport, with quantifiable, dose-dependent relationships between LDLR expression levels and therapeutic delivery efficiency. This approach is particularly advantageous for neurodegenerative disease therapeutics where consistent, high-concentration CNS penetration is essential for clinical efficacy.
Evidence for (11)
Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis.
Use of LDL receptor-targeting peptide vectors for in vitro and in vivo cargo transport across the blood-brain barrier.
Flaviviruses are neurotropic, but how do they invade the CNS?
Delivery of low-density lipoprotein from endocytic carriers to mitochondria supports steroidogenesis
Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis
GLSP and GLSP-derived triterpenes attenuate atherosclerosis and aortic calcification by stimulating ABCA1/G1-mediated macrophage cholesterol efflux and inactivating RUNX2-mediated VSMC osteogenesis
mTOR inhibition reprograms cellular lipid homeostasis by inducing alternative lipid uptake and promoting cholesterol transport
Materno-fetal cholesterol transport during pregnancy
Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies
Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmonary Hypertension
Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes
Evidence against (4)
Antibody Engineering for Receptor-Mediated Transcytosis Across the Blood-Brain Barrier.
PCSK9 in metabolism and diseases.
Functions of lipoprotein receptors in neurons
News on the molecular regulation and function of hepatic low-density lipoprotein receptor and LDLR-related protein 1